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The distribution and dynamics of the cytotoxic T lymphocyte (CTL) response to hepatitis B surface antigen (HBsAg) were studied in mice
after intramuscular DNA immunization and after hepatic infection by a recombinant adenovirus that expresses the hepatitis B virus genome
(Ad-HBV). CTLs specific for HBsAg accumulate preferentially in the spleen after DNA immunization but are primarily intrahepatic after
Ad-HBV infection. The secondary CTL response to Ad-HBV in DNA-primed mice is characterized by rapid depletion of effector CTLs from
the spleen, and their expansion in the liver where they cause hepatitis, secrete interferon gamma (IFNg), and inhibit HBV gene expression.
Suppression of HBsAg synthesis is accompanied by disappearance of intrahepatic IFNg-producing CTLs and their reaccumulation in the
spleen. The data suggest a possible explanation for the paucity and functional deficiency of HBV-specific CTLs in the periphery during
chronic HBV infection, and that the severity of infection can be worsened by a preexisting CTL response if neutralizing antibody is not also
present.
D 2005 Elsevier Inc. All rights reserved.
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The hepatitis B virus (HBV) is an enveloped, non-
cytopathic virus that causes acute and chronic liver disease
and hepatocellular carcinoma (Chisari, 2000; Chisari and
Ferrari, 1995). The cytotoxic T lymphocyte (CTL) response
is thought to be responsible for both viral clearance and liver
disease during HBV infection (Chisari, 2000; Chisari and
Ferrari, 1995). Indeed, it has been well documented that
patients with acute viral hepatitis, who successfully clear the
virus, mount a polyclonal and multispecific CTL response
(Bertoletti et al., 1991; Chisari and Ferrari, 1995; Maini et0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.01.004
* Corresponding author. Fax: +1 858 784 2160.
E-mail address: fchisari@scripps.edu (F.V. Chisari).al., 1999; Missale et al., 1993; Penna et al., 1991;
Rehermann et al., 1995) while it is weak or oligoclonal in
patients who are chronically infected (Penna et al., 1991;
Rehermann et al., 1995, 1996). Furthermore, adoptive
transfer of HBV-specific CTLs into HBV transgenic mice
induces viral clearance by noncytolytic, IFNg-mediated
antiviral mechanisms and by inducing a necroinflammatory
liver disease (Ando et al., 1993, 1994; Guidotti et al., 1994,
1996). Finally, it has been shown that depletion of CD8+ T
cells at the peak of viremia delayed viral clearance and liver
disease in an acutely HBV-infected chimpanzee (Thimme et
al., 2003).
Interestingly, the frequency of HBV-specific CTL in the
peripheral blood of acutely infected patients is relatively low
compared to virus infections such as HIVor CMV, and they
only appear in the blood after most of the virus has been05) 293–300
M. Isogawa et al. / Virology 333 (2005) 293–300294eliminated (Webster et al., 2000). Furthermore, CTLs are
hard to detect in the blood of chronically infected patients,
but they are readily detectable in the liver (Maini et al.,
2000), suggesting that they might be removed from the
circulation due to antigen recognition in the infected liver.
The current study was designed to address the impact of
viral antigen recognition in the liver, i.e., at the site of
antigen synthesis, or in peripheral lymphoid tissue on the
number and function of specific CTLs in each compartment.Results
Kinetics and distribution of the primary HBV
ENV28-specific CTL response induced by DNA
immunization and Ad-HBV infection
Groups of 3 to 4 male B6D2 mice were either injected
intramuscularly with 100 Ag of plasmid encoding the HBV
middle envelope protein (pCMV-S2.S) or they were infected
intravenously with 2  109 pfu of a replication defective
recombinant adenovirus vector that encodes a 1.3-fold-
overlength HBV genome and replicates the virus in the liver
(Ad-HBV). The frequency of envelope (ENV)-specific
CTLs in the liver, blood, spleen, and draining lymph nodes
were determined at various time points after DNA immu-
nization or Ad-HBV infection using ENV28 dimers that
recognize TCRs specific for ENV28-Ld complex.
DNA immunization
As shown in Figs. 1A1 and 1A2, ENV28-specific CTLs
were induced by day 7 after DNA immunization in all of the
compartments examined. Importantly, CD8+ ENV28-spe-
cific CTLs constituted 0.04% of the total number of
popliteal lymph node cells (Supplementary Fig.1S2) on
day 7, in contrast to 0.74% of the number of IHLs (Fig. 1A1
and Supplementary Fig.1S2). Furthermore, the CTLs were
significantly more prevalent in the liver than they were in
the peripheral blood and the spleen on days 7 (P b 0.05)
and 14 (P b 0.01) (Fig. 1A1 and Supplementary Figs. 1S2
and 1S3), reaching as high as 1.5% of the total IHL
population on day 14. Nonetheless, the total number of
ENV28-specific CTLs was at least 20-fold higher in the
spleen than in the liver on days 7 and 14 (Fig. 1A2) because
of the larger number of lymphocytes in that organ.
Importantly, most of the ENV28-specific CTLs were shown
to produce IFNg upon ENV28 peptide stimulation (Fig.
1A3), but no more than 25% of them were CD69+ (Fig.
1A4), suggesting that most of them were not recently
activated.
Ad-HBV infection
Intravenous Ad-HBV infection is a highly effective way
to deliver transcriptionally active HBV genomes to the
hepatocyte (Sprinzl et al., 2001). As shown in Fig. 2A, HBV
RNAwas detectable in the liver by Northern blot analysis asearly as 1 day after Ad-HBV infection, and it increased until
day 5 after which it declined but remained detectable for the
duration of the experiment. Infection was associated with a
modest necroinflammatory disease that began between days
3 and 5 and persisted for the duration of the experiment. In
contrast to the CTL response after DNA immunization, Ad-
HBV infection induced a CTL response that was almost
exclusively detectable in the liver (Fig. 1B). As shown in
Figs. 1B1, 1B2, and Supplementary Fig.1S1, the CTLs were
marginally detectable in the liver at very low levels on day
5 after infection, they increased on days 7 and 14 further,
and their absolute number stabilized on day 28. Notably,
throughout the entire experiment, ENV28-specific CTLs
were never detected in the lymph nodes (Supplementary
Fig.1S2) or in the spleen (Figs. 1B and 1B2 and
Supplementary Figs. 1S1 to S3) and they were only
transiently detected at very low levels in the blood on day
7 (Fig. 1B2 and Supplementary Fig.1S2). Interestingly, the
peak number of intrahepatic ENV28-specific CD8+ T cells
on day 14 after Ad-HBV infection (Fig. 1B2) was virtually
identical to the peak number of their splenic counterparts
after DNA immunization (Fig. 1A2). Furthermore, in
contrast to the splenic CTLs induced by DNA immuniza-
tion, relatively few (36.6 F 17.3%) of the day 7 Ad-HBV-
induced intrahepatic CTLs were able to produce IFNg and
this fraction progressively decreased thereafter, failing to
5.8% by day 28 (Fig. 1B3). In contrast, more than 80% of
the ENV28-specific CTLs were CD69+ (Fig. 1B4),
suggesting that they had recently encountered antigen,
and raising the possibility that continuous antigen exposure
may have triggered their functional impairment. Thus,
these results demonstrate that intramuscular DNA immu-
nization and intrahepatic Ad-HBV infection induced an
HBV ENV28-specific CTL response with similar kinetics,
but very different tissue distribution, activation status, and
function.
Kinetics, distribution, and function of the secondary HBV
ENV28-specific CTL response induced by Ad-HBV infection
after priming by DNA immunization
Next, we examined the functional impact of antigen
presentation on previously DNA-primed HBV ENV28-
specific T cells by HBV-producing cells in the liver and
by HBV-nonproducing cells in the spleen where cross-
presentation of antigen is likely to occur.
Accordingly, groups of 3 to 4 mice were primed intra-
muscularly by plasmid DNA to induce a CTL response to
HBsAg exactly as described in Fig. 1A. Fourteen days later
the mice were infected intravenously with 2 109 pfu of Ad-
HBV, exactly as described in Fig. 1B. As shown in Figs. 3A3,
3A4, 3B3, and 3B4 on day 0 of this experiment (14 days after
DNA immunization), virtually all of the DNA-primed
ENV28-specific CTLs produced IFNg following ENV28
peptide stimulation, while fewer than 25% of them expressed
CD69, as shown in Figs. 1A3 and 1A4. However, striking
Fig. 1. Comparison of ENV28-specific CTL response induced by intramuscular DNA immunization and Ad-HBV infection. Mice were either intramuscularly
injected with 100 Ag of pCMV-S2.S DNA (A) or intravenously infected with 2  109 pfu of Ad-HBV (B). The kinetics, distribution, function, and activation
status of ENV28-specific CTLs in the liver (white bar), blood (black bar), and spleen (hatched bar) were examined at indicated time points after treatments.
First and second panels represent the percentage in total lymph mononuclear cells (A1 and B1) and the total number (A2 and B2) of ENV28-specific CTLs
detected by ENV28 dimer that recognize TCR specific for ENV28-Ld complex. Note that the total number is expressed on logarithmic scale. Third and forth
panels represent the fraction of ENV28-specific CTLs that produce IFNg upon ENV28 peptide stimulation (A3 and B3) and express CD69 (A4 and B4), and
expressed as a percentage of the ENV28 dimer-positive cells.
M. Isogawa et al. / Virology 333 (2005) 293–300 295changes occurred in the intrahepatic and splenic ENV28-
specific CD8+ T cell populations soon after Ad-HBV
infection. On day 3, the relative (Fig. 3A1 and Supplementary
Fig.3S) and absolute number (Fig. 3A2) of ENV28-specific
CTLs in the liver did not significantly change (P N 0.05), all
of which continued to produce IFNg at preinfection levels(Fig. 3A3). However, there was an 11-fold increase in the
fraction of ENV28-specific CTLs that expressed the CD69
activation marker (Fig. 3A4). Importantly, as shown in Fig.
2B, this corresponded with a strong increase of HBV gene
expression in the liver and a slight increase in serum ALT
activity, suggesting the onset of a necroinflammatory liver
Fig. 2. Kinetics of HBV gene expression, antigenemia, and liver disease.
Immunologically naRve (A) and pCMV-S2.S-primed (B) mice were
intravenously infected with 2  109 pfu of Ad-HBV on day 0. Total liver
RNA extracted from the liver of mice at indicated time points after the Ad-
HBV infection was analyzed for HBV and GAPDH transcripts by Northern
blot analysis. ALT activity is expressed in units per liter (U/L).
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the preexisting DNA-primed intrahepatic CTLs had seen
and responded to antigen during the first 3 days after
infection. By day 5 after infection, the relative and
absolute number of intrahepatic ENV28+ CTLs increased
up to 37-fold above preinfection levels (Figs. 3A1 and
3A2) and they continued to express CD69 and produce
IFNg (Figs. 3A3 and 3A4), presumably reflecting the
continuing high level of viral mRNA in the liver (Fig. 2B).
Importantly, there was a large increase in serum ALT
activity at this time (Fig. 2B), presumably reflecting the
cytolytic functions of the activated CTLs. The number of
ENV28-specific CTLs increased further, peaked on day 7,
and contracted by day 28, while they remained CD69+
(Fig. 3A3), suggesting that they were continually exposed
to antigen. Nonetheless, the viral mRNA content of the
liver decreased markedly during this period of time and the
serum ALT activity began to decline (Fig. 2B), presumably
reflecting the elimination of HBV-producing hepatocytes.
Strikingly, however, as the total number of ENV28-specific
CTLs increased, the fraction of IFNg-producing ENV28-
specific CTLs decreased from 66.8% on day 5 to 10.2%
on day 14 (Fig. 3A3). Collectively, those results suggest
that the ENV28-specific IFNg-producing cells may have
exited the liver and were replaced by ENV28-specific
IFNg-nonproducers, or that the IFNg-producing capacity
of the CTLs requires continuing recognition of antigen at
levels much higher than those needed for expression of
CD69 or that IFNg production was suppressed as a result
of prolonged antigen stimulation in the liver, since theENV28-specific CD8+ T cells remained CD69+ at these
time points.
In contrast to these findings, the splenic ENV28-
specific CTL population displayed very different dynamics
from its counterparts in the liver. As shown in Figs. 3B1
and 3B2, by day 3 after Ad-HBV infection, when ENV28-
specific CTLs were starting to accumulate in the liver (Fig.
3A2), the entire preexisting ENV28-specific CTL popula-
tion disappeared from the spleen (Fig. 3B2) and peripheral
blood (not shown). The disappearance of ENV28-specific
CTLs presumably reflect an antigen-specific event rather
than a global clearance of CTLs from the spleen, since the
total number of CD8+ T cells in the spleen was
unchanged. The CTLs rapidly returned, however, by day
5 (Fig. 3B2 and Supplementary Fig.3S) but they did not
produce IFNg following peptide stimulation (Fig. 3B3), and
they were mainly CD69 (Fig. 3B4), both of which
contrasted strikingly with the CTLs in the liver at that time
point (Figs. 3A3 and 3A4). The fraction of IFNg-producing
CTLs in the spleen increased slightly but significantly on
day 7 (P b 0.01) (Fig. 3B3) when the corresponding CTLs
were decreasing in the liver, and they returned to baseline
levels by day 14 (Fig. 3B3) when the number of IFNg-
producing CTLs in the liver was at their low point.
Interestingly, almost same number of IFNg-producing CTLs
were gained in the spleen (2.2  105) and lost from the liver
(1.86  105) between day 5 and day 14. Whether this
represents redistribution of these CTLs between compart-
ments or functional modulation of the CTLs within each
compartment remains to be determined.Discussion
The current results illustrate that very different dynamic
changes occur in virus-specific CTL populations depending
on whether they are located at the site of virus production or
in distant lymphoid compartments that can be reached by
secreted viral antigens and where cross presentation is likely
to occur.
Initially, we compared the primary immune response to
HBsAg in mice that we either immunized intramuscularly
with a noninfectious plasmid or we infected intravenously
with a replication defective adenovirus vector that expresses
HBV antigens exclusively in the liver from which they are
secreted into the circulation. As illustrated in Fig. 1A, DNA
immunization induced CTLs that were detectable in the
draining lymph nodes, blood, spleen, and liver within 5–7
days after injection. Most of the CTLs were located in the
spleen (Fig. 1A2), although they were also detectable in the
liver where they represented a much larger proportion of the
lymphoid population than their counterparts in the spleen
(Fig. 1A1). This is compatible with the notion that CTLs are
induced in the lymphoid tissue and removed from the
circulation by the liver (Belz et al., 1998; Huang et al.,
1994; Mehal et al., 1999, 2001). In contrast, as shown in
Fig. 3. Comparison of the secondary ENV28-sepcific CTL response in the liver and the spleen. Mice were primed pCMV-S2S and 14 days later infected with
Ad-HBV as described in the legend to Fig. 1B. The kinetics, function, and activation status of the ENV28-specific CTLs in the liver (A) and spleen (B) were
examined as described in the legend to Fig. 1.
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response that was detectable essentially only in the liver
(Figs. 1B1 and 1B2, see also Supplementary Fig.1S),
presumably reflecting either intrahepatic CTL induction as
suggested by Bertolino and his colleagues (1998, 2001), or
extrahepatic CTL induction and rapid homing to the site of
antigen synthesis in the liver. Whether the differences in the
kinetics and location of the HBV ENV28-specific CTLsunder these different immunization conditions reflect the
site of antigen synthesis or the amount of antigen produced
remain to be determined. It is interesting that the kinetics of
accumulation of HBV-specific CTLs in the liver during the
Ad-HBV infection corresponded with the induction of a
mild liver disease and a modest reduction in the level of
viral gene expression during the 4-week observation period
(Fig. 2A). Since most of the intrahepatic ENV28-specific
M. Isogawa et al. / Virology 333 (2005) 293–300298CTLs expressed CD69 (Fig. 2B, fourth panel) on day 7 after
Ad-HBV infection, we presume that they recognized antigen
in the liver and probably contributed to the mild hepatitis
and slight downregulation of viral gene expression that
occurred in that setting.
The dynamic changes that occurred in the intrahepatic
and splenic CTL populations in the DNA-primed mice
following Ad-HBV infection are particularly interesting.
The primed CTLs in both compartments were quite similar
to each other at the time of infection since both were largely
composed of CD69-negative T cells that could produce
IFNg following peptide stimulation (Figs. 1A3, 1A4, 1B3,
1B4, 3A3, 3A4, 3B3, and 3B4). Their subsequent behavior
was not at all similar, however. As shown in Fig. 3A, the
intrahepatic CTLs sequentially became activated (CD69+)
(Fig. 3A4), after which they greatly expanded, and
ultimately lost the ability to produce IFNg following peptide
stimulation (Fig. 3A3). While CTL activation and expansion
were predictable, we do not know if the expansion occurred
in the liver or elsewhere and the expanding CTLs homed to
the liver. We also do not understand whether the subsequent
decrease in the number of IFNg-producing CTLs of the
intrahepatic CTL in the liver reflects the induction of anergy
or the selective death or exit of these CTLs from the liver.
We favor the anergy hypothesis because the other two
alternatives would require the simultaneous replacement of
the dying or exiting CTLs by an equal number of IFNg
nonproducing CTLs which we consider unlikely. In
confirmation of the anergy hypothesis, we have recently
shown that the IFNg-producing capacity of HBV ENV28-
specific CD8 T cells is rapidly lost after adoptive transfer
and entry into the HBV transgenic mouse liver (Isogawa and
Chisari, unpublished observations). Thus, we suggest that
antigen presentation in the liver induces anergy in effector
CTLs as it does to naRve CD8+ T cells (Bertolino et al.,
1998, 2001). Further experiments are required to determine
if these interesting changes are restricted to the primed
effector-memory CTL population, as studied in these
experiments, or whether they also extends to central
memory CTLs as well.
The splenic CTL population behaved entirely differently
following Ad-HBV infection. Indeed, as shown in Figs. 3B1
and 3B2, ENV28-specific CTLs completely disappeared
within 3 days of infection at which time the intrahepatic
CTL population was becoming activated and starting to
expand. This was not a nonspecific effect, since the total
number of CD8+ T cells in the spleen did not change at this
time point. Furthermore, 2 days later, ENV28-specific CTLs
reappeared in the spleen, but they were largely dysfunc-
tional since most of them could not produce IFNg after
peptide stimulation (Fig. 3B3). Ultimately, the splenic CTLs
reacquired the ability to produce IFNg; however, this
occurred precisely when viral mRNA and IFNg-producing
CTLs were disappearing from the liver (Fig. 2B).
The seemingly mirror-image behavior of the hepatic and
splenic CTL populations throughout the course of the Ad-HBV infection suggests that reciprocal movement of CTL
populations may have occurred between the two sites. For
example, the virtually quantitative disappearance of splenic
CTLs may have been due to their exit from the spleen and
rapid homing to the liver upon activation by sudden
exposure to circulating or cross-presented antigen. Alter-
natively, they could have experienced massive cell death in
situ for the same reason. At the other end of the time-course,
the splenic CTLs reacquired the ability to produce IFNg,
just as the intrahepatic CTLs were losing that function.
Again reciprocal movement from liver to spleen or func-
tional changes in the CTL population in situ could account
for these findings.
In addition to raising these interesting fundamental
questions, the current results may also provide an explan-
ation for the relatively low frequency of HBV and HCV-
specific CTLs in the blood in acutely and, especially,
chronically infected patients (Penna et al., 1991; Rehermann
et al., 1995, 1996). If, as shown in this study, most of those
virus-specific CTLs are located in the liver and most of the
circulating CTLs are functionally defective, the current
results would suggest that much greater emphasis should be
given to defining the intrahepatic CTL population in those
patients, and that therapeutic modalities that interfere with
viral antigen production by the liver may have a much better
chance to restore and rebalance immunological function in
such patients than antiviral agents that merely interrupt viral
replication.
Finally, the more severe and prolonged liver disease we
observed in the DNA-immunized mice (Fig. 2B) relative to
the nonimmunized mice (Fig. 2A) after Ad-HBV infection
reveals an underappreciated danger of immunization strat-
egies intended to induce a CTL response to a virus without a
corresponding neutralizing antibody response. Indeed any
anti-HBV antibodies that may have been induced by DNA
immunization in the current study would not protect the
mice against the Ad-HBV infection. Thus, viral spread
would be unopposed by antibody in those animals such that
large numbers of susceptible cells would be infected until
the preexisting CTLs expanded sufficiently to destroy them.
This could have disastrous consequences if it led to the
synchronized destruction of large numbers of cells from a
vital organ, especially if the regenerating capacity of those
cells is less vigorous than the hepatocyte.Materials and methods
Mice
C57BL/6 mice (H-2b) were mated with B10.D2 mice (H-
2d) to produce the F1 hybrids (designated B6D2) that were
used in this study. In all experiments, the mice were age (8–
10 weeks) and sex (male) matched, before experimental
manipulation. All animals were housed in pathogen-free
rooms under strict barrier conditions.
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The H-2d-restricted HBV envelope (ENV)-specific CTL
epitope, ENV28 (IPQSLDSWWTSL), reported previously
(Ando et al., 1993; Ishikawa et al., 1998), was purchased
from Research Genetics (Huntsville, AL). A plasmid
(pCMV-S2.S) that expresses the middle and major envelope
proteins (preS2/S) of HBV under the transcriptional control
of the CMV immediate early promoter (generously provided
by R. Whalen and H. Davis; Davis et al., 1995; Michel et
al., 1995) was used to immunize mice (see below). A
replication-defective adenovirus vector (Ad-HBV) contain-
ing a 1.3-fold-overlength replication competent HBV
genome that induces HBV antigen expression exclusively
in the liver (Protzer et al, unpublished observations) has
been previously described (Sprinzl et al., 2001).
Plasmid DNA immunization and Ad-HBV infection
Mice were immunized by injecting 50 Ag of pCMV-S2.S
plasmid DNA into the regenerating tibialis anterior muscles
(100 Ag/mouse) 5 days after injection of cardiotoxin (Davis
et al., 1995; Kakimi et al., 2002). For Ad-HBV infection, 2
109 plaque forming units (pfu) of Ad-HBV were injected
intravenously, as described (Sprinzl et al., 2001).
Lymphomononuclear cell preparation
Single cell suspensions were prepared from the periph-
eral blood, spleen, liver, popliteal, and portal lymph nodes
as previously described (Bertolino et al., 2001; Kakimi et
al., 2000, 2002). Briefly, peripheral blood leukocytes
(PBLs) were prepared from whole anticoagulated blood by
lysis of red blood cells with ACK lysis buffer (0.15 M
NH4Cl, 10.0 mM KHCO3, 0.1 mM Na2EDTA at pH 7.2).
Cells were washed twice with phosphate-buffered saline
(PBS) and used for further analysis. Spleen cells were
isolated by compressing the spleen against the bottom of a
petri dish with the plunger of a 1-ml syringe. For intra-
hepatic lymphocyte (IHL) isolation, livers were first
perfused with 10 ml of PBS via the portal vein to remove
circulating lymphocytes and the liver cell–cell suspension
was pressed through a 70-Am Cell Strainer (Becton Dick-
inson, Franklin Lakes, NJ) and digested with 10 ml of RPMI
1640 medium (Life Technologies, Gaithersburg, MD),
containing 0.02% (w/v) collagenase IV (Sigma, St. Louis,
MO) and 0.002% (w/v) DNase I (Sigma), for 40 min at 37
8C. Cells were washed with RPMI 1640 and then underlaid
on 24% (w/v) metrizamide (Sigma) in PBS. After centrifu-
gation for 20 min at 1500  g, the IHLs were isolated at the
interface. Contaminating red blood cells were lysed by ACK
lysis buffer and the remaining lymphmononuclear cells were
washed twice with RPMI 1640 medium and used for further
analysis. Lymph node cells were isolated by compressing
the lymph nodes through a 70-Am Cell Strainer (Becton
Dickinson, Franklin Lakes, NJ) and were washed threetimes with phosphate-buffered saline (PBS) and used for
further analysis.
Dimer and intracellular IFNc staining
Recombinant soluble dimeric H-2Ld–Ig Fusion Protein
(BD/PharMingen, San Diego, CA) complexed with HBV
ENV28 peptide (ENV28 dimer) was prepared according to
the manufacturer’s instructions. Briefly, the dimeric H-
2Ld–Ig fusion protein was incubated with ENV28 peptide
at 10-fold molar excess for at least 2 days at 4 8C.
Lymphmononuclear cells isolated from the liver, spleen, and
peripheral blood were incubated with a mixture containing
the ENV28 dimer, APC-conjugated anti-mouse CD8, and
FITC-conjugated anti-mouse CD69 antibodies (BD/Phar-
mingen, San Diego, CA) for 1 h on ice. After washing, the
cells were incubated for 30 min with PE-conjugated anti-
mouse IgG at 4 8C to detect ENV28 dimer-positive cells.
Dimer without peptide was used as a control. Intracellular
IFNg staining was performed after 5 h of ENV28 peptide
stimulation as previously described (Kakimi et al., 2002).
Cells were acquired using a FACSCalibur flow cytometer
(Becton Dickinson) and data were analyzed using CELL-
Quest software (Becton Dickinson). The primary FACS
plots are provided as Supplementary Figs. 1S and 3S. All
experiments were performed in triplicate. The means and
standard deviation of each group are displayed as bar graph
in this paper.
Analysis of HBV gene expression
Total liver RNA was extracted from snap-frozen mouse
livers taken at various time points after treatments and
subjected to Northern blot analysis as previously described
(Guidotti et al., 1994).
Serum alanine aminotransferase activity
The extent of hepatocellular injury was monitored by
measuring serum alanine aminotransferase (sALT) activity
at multiple time points after treatment. The sALT activity
was measured at 30 8C on a SpectraMax Plus spectropho-
tometer (Molecular Devices, Sunnyvale, CA) using the ALT
Infinity Reagent (Sigma) following the manufacturer’s
instructions.
Statistical analysis
The results were analyzed by the Student’s t test using
Microsoft Excel (Redmond, WA) software.Acknowledgments
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